Made in China: Envirotainer teams with drug and API shipper Air China Cargo

By Gareth Macdonald

- Last updated on GMT

Picture credit iStock/Shawnlio
Picture credit iStock/Shawnlio
Envirotainer has partnered with Air China Cargo in deal that will see local and international drug and API makers use its range of cold chain shipping containers.

The agreement – financial terms of which were not disclosed – is designed to support the airline's development of a new import-export route for active pharmaceutical ingredients (API) and finished drug products. The new route will include hubs in Beijing, Shanghai, Singapore, Frankfurt and Geneva.

Bourji Mourad, Head of Global Partner Management & Compliance at Envirotainer, said: “The partnership with Air China Cargo is another positive step forward in China, APAC and indeed worldwide, as more stations and capacity are added to the portfolio in order to support the growing demands.

Mourad added that: “Our Singapore-based Global Partner Manager Paul Seet will be assisting Air China Cargo with the roll out of this agreement as well as managing the partnership between our two companies.”

Sweden-based Envirotainer opened a service center in Shanghai completing a busy year of expansion that also saw it set up a US headquarters in New York and an office in Singapore.

Demand and prices

Envirotainer’s global growth has been driven by growing industry demand for its range of cold chain shipping technologies.

Last April​ the firm said “strong demand for our active temperature-controlled container solutions” and a desire to invest had prompted it to increase the price of its RKN e1 and RAP e2 containers by 3%. The new prices came into effect in October.

Related news

Show more

Related products

show more

Ultra Low Temperature Packaging solutions

Ultra Low Temperature Packaging solutions

Content provided by Almac Group | 12-Feb-2024 | Case Study

Advanced Therapy Medicinal Products (ATMPs) offer ground-breaking opportunities for treating injuries and disease, in particular for cases of severe, untreatable...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Follow us

Products

View more

Webinars